Journal of Clinical Oncology, Vol 18, Issue 2
(January), 2000: 317
© 2000 American Society for Clinical Oncology
European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma
By James M. Foran,
Ama Z. S. Rohatiner,
David Cunningham,
Razvan A. Popescu,
Philippe Solal-Celigny,
Michele Ghielmini,
Bertrand Coiffier,
Peter W. M. Johnson,
Christian Gisselbrecht,
Felix Reyes,
John A. Radford,
Eric M. Bessell,
Bertrand Souleau,
Aziz Benzohra,
T. Andrew Lister
From the Imperial Cancer Research Fund Medical Oncology Unit, St Bartholomew’s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James’ University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud, Lyon; Department of Hematology, Hopital St Louis, Paris; Department of Hematology, Hopital Henri Mondor, Creteil; Service d’Hematologie, Hopital d’Instructions des Armees Percy, Clamart; and Roche Pharmaceuticals, Neuilly, France; and Servizio Oncologico, Ospedale San Giovanni, Bellinzona, Switzerland.
Address reprint requests to James M. Foran, MD, ICRF Medical Oncology Unit, St Bartholomew’s Hospital, 45 Little Britain, London EC1A 7BE United Kingdom; email foran{at}icrf.icnet.uk
PURPOSE: Mantle-cell lymphoma (MCL), immunocytoma (IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that express CD20 and are incurable with standard therapy. A multicenter phase II study was conducted to assess the toxicity and the overall response rates (RR) and complete response (CR) rates to rituximab (chimeric anti-CD20 monoclonal antibody).
PATIENTS AND METHODS: Between January 1997 and January 1998, 131 patients with newly diagnosed MCL (MCL1; n = 34) and previously treated MCL (MCL2; n = 40), IMC (n = 28), and SLL (n = 29) received rituximab 375 mg/m2/wk for 4 weeks via intravenous infusion. Restaging studies were performed 1 and 2 months after treatment. An analysis of the duration of response was conducted in December 1998.
RESULTS: Eleven patients were unassessable, including one who died of splenic rupture after the first infusion. The RR among the 120 assessable patients was 30% (36 of 120 patients). The RR by histology was as follows: MCL1, 38%; MCL2, 37%; IMC, 28%; and SLL, 14%. Ten patients, all with MCL, achieved CR. The median duration of response in MCL was 1.2 years. Immediate side effects were common and usually responded to adjustments in the infusion rate. There were 31 episodes of infection after treatment; most cases were mild. Cardiac arrhythmia and ophthalmologic side effects occurred in 10 and nine patients, respectively, including one case of severe loss of visual acuity.
CONCLUSION: Single-agent rituximab has moderate activity in MCL and IMC but only limited activity in SLL. The duration of response in MCL was similar to that previously reported in follicular lymphoma. Its use in combination with cytotoxic chemotherapy to increase the CR rate is warranted in MCL and IMC.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
L. E. Damon, J. L. Johnson, D. Niedzwiecki, B. D. Cheson, D. D. Hurd, N. L. Bartlett, A. S. LaCasce, K. A. Blum, J. C. Byrd, M. Kelly, et al.
Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909
J. Clin. Oncol.,
December 20, 2009;
27(36):
6101 - 6108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wang, Y. Oki, B. Pro, J. E. Romaguera, M. A. Rodriguez, F. Samaniego, P. McLaughlin, F. Hagemeister, S. Neelapu, A. Copeland, et al.
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol.,
November 1, 2009;
27(31):
5213 - 5218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Treon
How I treat Waldenstrom macroglobulinemia
Blood,
September 17, 2009;
114(12):
2375 - 2385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Treon, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, P. Sheehy, M. Nelson, M. Willen, J. Matous, J. Mattern II, J. G. Diener, et al.
Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
J. Clin. Oncol.,
August 10, 2009;
27(23):
3830 - 3835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, C. Gisselbrecht, A. Laurell, F. Offner, A. Strahs, A. Berkenblit, et al.
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol.,
August 10, 2009;
27(23):
3822 - 3829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, J. P. Leonard, L. Fayad, B. Coiffier, M.-O. Petillon, M. Coleman, S. J. Schuster, M. J.S. Dyer, H. Horne, N. Teoh, et al.
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
J. Clin. Oncol.,
July 10, 2009;
27(20):
3346 - 3353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. MANOLOPOULOS, I. P GOMATOS, E. LEANDROS, L. ALEVIZOS, N. GEORGIOU, J. GIOTAKIS, and E. FEREKIDIS
Use of Rituximab in Combination with Conventional Chemotherapy for the Treatment of Non-Hodgkin's Lymphoma of the Head and Neck
In Vivo,
May 1, 2009;
23(3):
475 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Treon, A. R. Branagan, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, B. Turnbull, P. Wasi, C. Emmanouilides, S. R. Frankel, A. Lister, et al.
Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia
Blood,
April 16, 2009;
113(16):
3673 - 3678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Treon, J. D. Soumerai, A. R. Branagan, Z. R. Hunter, C. J. Patterson, L. Ioakimidis, F. M. Briccetti, M. Pasmantier, H. Zimbler, R. B. Cooper, et al.
Thalidomide and rituximab in Waldenstrom macroglobulinemia
Blood,
December 1, 2008;
112(12):
4452 - 4457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. G. Till, M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood, H. A. Greisman, X. Qian, S. E. James, A. Raubitschek, S. J. Forman, et al.
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Blood,
September 15, 2008;
112(6):
2261 - 2271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med.,
August 7, 2008;
359(6):
613 - 626.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Hsi, R. Steinle, B. Balasa, S. Szmania, A. Draksharapu, B. P. Shum, M. Huseni, D. Powers, A. Nanisetti, Y. Zhang, et al.
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Clin. Cancer Res.,
May 1, 2008;
14(9):
2775 - 2784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al.
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Blood,
October 1, 2007;
110(7):
2569 - 2577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Gerard, A. Berezne, L. Galicier, V. Meignin, M. Obadia, N. De Castro, C. Jacomet, R. Verdon, I. Madelaine-Chambrin, E. Boulanger, et al.
Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial
J. Clin. Oncol.,
August 1, 2007;
25(22):
3350 - 3356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Singh, L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, Z. Al-Kadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, et al.
Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
Cancer Res.,
March 15, 2007;
67(6):
2872 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dreger, M. Rieger, B. Seyfarth, M. Hensel, M. Kneba, A. D. Ho, N. Schmitz, and C. Pott
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Haematologica,
January 1, 2007;
92(1):
42 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al.
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol.,
October 20, 2006;
24(30):
4867 - 4874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell, S. M. Geyer, M. J. Maurer, P. J. Kurtin, I. N.M. Micallef, P. Stella, P. Etzell, A. J. Novak, C. Erlichman, and T. E. Witzig
Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6056 - 6063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. L. Yee and S. M. O'Brien
Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
August 1, 2006;
81(8):
1105 - 1129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Romaguera, L. Fayad, M. A. Rodriguez, K. R. Broglio, F. B. Hagemeister, B. Pro, P. McLaughlin, A. Younes, F. Samaniego, A. Goy, et al.
High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
J. Clin. Oncol.,
October 1, 2005;
23(28):
7013 - 7023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig
Current Treatment Approaches for Mantle-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6409 - 6414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tassone, P. Neri, J. L. Kutok, O. Tournilhac, D. D. Santos, E. Hatjiharissi, V. Munshi, S. Venuta, K. C. Anderson, S. P. Treon, et al.
A SCID-hu in vivo model of human Waldenstrom macroglobulinemia
Blood,
August 15, 2005;
106(4):
1341 - 1345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig, S. M. Geyer, I. Ghobrial, D. J. Inwards, R. Fonseca, P. Kurtin, S. M. Ansell, R. Luyun, P. J. Flynn, R. F. Morton, et al.
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
J. Clin. Oncol.,
August 10, 2005;
23(23):
5347 - 5356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Ganti, P. J. Bierman, J. C. Lynch, R. G. Bociek, J. M. Vose, and J. O. Armitage
Hematopoietic stem cell transplantation in mantle cell lymphoma
Ann. Onc.,
April 1, 2005;
16(4):
618 - 624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Dimopoulos, R. A. Kyle, A. Anagnostopoulos, and S. P. Treon
Diagnosis and Management of Waldenstrom's Macroglobulinemia
J. Clin. Oncol.,
March 1, 2005;
23(7):
1564 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Hainsworth, S. Litchy, D. W. Shaffer, V. L. Lackey, M. Grimaldi, and F. A. Greco
Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma--A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network
J. Clin. Oncol.,
February 20, 2005;
23(6):
1088 - 1095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher
Mantle Cell Lymphoma: At Last, Some Hope for Successful Innovative Treatment Strategies
J. Clin. Oncol.,
February 1, 2005;
23(4):
657 - 658.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Treon, C. Emmanouilides, E. Kimby, A. Kelliher, F. Preffer, A. R. Branagan, K. C. Anderson, S. R. Frankel, and On behalf the Waldenstrom's Macroglobulinemia Clin
Extended rituximab therapy in Waldenstrom's macroglobulinemia
Ann. Onc.,
January 1, 2005;
16(1):
132 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard
Targeting CD20 in Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and the Use of Radioimmunoconjugates
Hematology,
January 1, 2005;
2005(1):
335 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Forstpointner, M. Dreyling, R. Repp, S. Hermann, A. Hanel, B. Metzner, C. Pott, F. Hartmann, F. Rothmann, R. Rohrberg, et al.
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Blood,
November 15, 2004;
104(10):
3064 - 3071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Brugger, J. Hirsch, F. Grunebach, R. Repp, P. Brossart, W. Vogel, H.-G. Kopp, M. G. Manz, M. Bitzer, G. Schlimok, et al.
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study
Ann. Onc.,
November 1, 2004;
15(11):
1691 - 1698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tobinai, T. Igarashi, K. Itoh, Y. Kobayashi, M. Taniwaki, M. Ogura, T. Kinoshita, T. Hotta, K. Aikawa, K. Tsushita, et al.
Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
Ann. Onc.,
May 1, 2004;
15(5):
821 - 830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Mone, P. Huang, H. Pelicano, C. M. Cheney, J. M. Green, J. Y. Tso, A. J. Johnson, S. Jefferson, T. S. Lin, and J. C. Byrd
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
Blood,
March 1, 2004;
103(5):
1846 - 1854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mangel, H. A. Leitch, J. M. Connors, R. Buckstein, K. Imrie, D. Spaner, M. Crump, N. Pennell, A. Boudreau, and N. L. Berinstein
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
Ann. Onc.,
February 1, 2004;
15(2):
283 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Conconi, G. Martinelli, C. Thieblemont, A. J. M. Ferreri, L. Devizzi, F. Peccatori, M. Ponzoni, E. Pedrinis, S. Dell'Oro, G. Pruneri, et al.
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
Blood,
October 15, 2003;
102(8):
2741 - 2745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Coleman, D. M. Goldenberg, A. B. Siegel, J. C. Ketas, M. Ashe, J. M. Fiore, and J. P. Leonard
Epratuzumab: Targeting B-Cell Malignancies through CD22
Clin. Cancer Res.,
September 1, 2003;
9(10):
3991s - 3994s.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
J. Immunol.,
August 1, 2003;
171(3):
1581 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mangel, R. Buckstein, K. Imrie, D. Spaner, E. Franssen, P. Pavlin, A. Boudreau, N. Pennell, D. Combs, and N. L. Berinstein
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation
Ann. Onc.,
May 1, 2003;
14(5):
758 - 765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Hainsworth, S. Litchy, J. H. Barton, G. A. Houston, R. C. Hermann, J. E. Bradof, and F. A. Greco
Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
J. Clin. Oncol.,
May 1, 2003;
21(9):
1746 - 1751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mavromatis and B. D. Cheson
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 1, 2003;
21(9):
1874 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Boye, T. Elter, and A. Engert
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
Ann. Onc.,
April 1, 2003;
14(4):
520 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tzankov, J. Krugmann, F. Fend, M. Fischhofer, R. Greil, and S. Dirnhofer
Prognostic Significance of CD20 Expression in Classical Hodgkin Lymphoma: A Clinicopathological Study of 119 Cases
Clin. Cancer Res.,
April 1, 2003;
9(4):
1381 - 1386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Manches, G. Lui, L. Chaperot, R. Gressin, J.-P. Molens, M.-C. Jacob, J.-J. Sotto, D. Leroux, J.-C. Bensa, and J. Plumas
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Blood,
February 1, 2003;
101(3):
949 - 954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, B. L. Peterson, V. A. Morrison, K. Park, R. Jacobson, E. Hoke, J. W. Vardiman, K. Rai, C. A. Schiffer, and R. A. Larson
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
Blood,
January 1, 2003;
101(1):
6 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A Krieger, J. M Merin, and I. Rabinowitz
Necrotizing fasciitis following rituximab therapy
Journal of Oncology Pharmacy Practice,
December 1, 2002;
8(4):
127 - 129.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. D. Hainsworth, S. Litchy, H. A. Burris III, D. C. Scullin Jr, S. W. Corso, D. A. Yardley, L. Morrissey, and F. A. Greco
Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
October 15, 2002;
20(20):
4261 - 4267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Igarashi, Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, Y. Sasaki, Y. Morishima, T. Murate, M. Kasai, N. Uike, et al.
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
Ann. Onc.,
June 1, 2002;
13(6):
928 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Dimopoulos, C. Zervas, A. Zomas, C. Kiamouris, N. A. Viniou, V. Grigoraki, C. Karkantaris, C. Mitsouli, D. Gika, J. Christakis, et al.
Treatment of Waldenstrom's Macroglobulinemia With Rituximab
J. Clin. Oncol.,
May 1, 2002;
20(9):
2327 - 2333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. Howard, J. G. Gribben, D. S. Neuberg, M. Grossbard, C. Poor, M. J. Janicek, and M. A. Shipp
Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival
J. Clin. Oncol.,
March 1, 2002;
20(5):
1288 - 1294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene
Blood,
February 1, 2002;
99(3):
754 - 758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, et al.
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
N. Engl. J. Med.,
January 24, 2002;
346(4):
235 - 242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology,
January 1, 2002;
2002(1):
241 - 262.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. M. Ansell, T. E. Witzig, P. J. Kurtin, J. A. Sloan, D. F. Jelinek, K. G. Howell, S. N. Markovic, T. M. Habermann, G. G. Klee, P. J. Atherton, et al.
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
Blood,
January 1, 2002;
99(1):
67 - 74.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Golay, M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, T. Barbui, A. Rambaldi, and M. Introna
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
Blood,
December 1, 2001;
98(12):
3383 - 3389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bellosillo, N. Villamor, A. Lopez-Guillermo, S. Marce, J. Esteve, E. Campo, D. Colomer, and E. Montserrat
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
Blood,
November 1, 2001;
98(9):
2771 - 2777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Huhn, C. von Schilling, M. Wilhelm, A. D. Ho, M. Hallek, R. Kuse, W. Knauf, U. Riedel, A. Hinke, S. Srock, et al.
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Blood,
September 1, 2001;
98(5):
1326 - 1331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Dhodapkar, J. L. Jacobson, M. A. Gertz, S. E. Rivkin, G. D. Roodman, J. M. Tuscano, M. Shurafa, R. A. Kyle, J. J. Crowley, and B. Barlogie
Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)
Blood,
July 1, 2001;
98(1):
41 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, T. Murphy, R. S. Howard, M. S. Lucas, A. Goodrich, K. Park, M. Pearson, J. K. Waselenko, G. Ling, M. R. Grever, et al.
Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity
J. Clin. Oncol.,
April 15, 2001;
19(8):
2153 - 2164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Jahrsdörfer, G. Hartmann, E. Racila, W. Jackson, L. Mühlenhoff, G. Meinhardt, S. Endres, B. K. Link, A. M. Krieg, and G. J. Weiner
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens
J. Leukoc. Biol.,
January 1, 2001;
69(1):
81 - 88.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Goel, S. Augustine, J. Baranowska-Kortylewicz, D. Colcher, B. J. M. Booth, G. Pavlinkova, M. Tempero, and S. K. Batra
Single-Dose versus Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using 131I-labeled Multivalent CC49 Single-chain Fvs
Clin. Cancer Res.,
January 1, 2001;
7(1):
175 - 184.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. D. Hainsworth
Monoclonal Antibody Therapy in Lymphoid Malignancies
Oncologist,
October 1, 2000;
5(5):
376 - 384.
[Abstract]
[Full Text]
|
|
|
|
